Intracellular delivery of peptide drugs using viral nanoparticles of bacteriophage P22: covalent loading and cleavable release

Jigang Wang,^{ab} Ti Fang,^a Ming Li,^{ab} Wenjing Zhang,^{ab} Zhi-Ping Zhang,^a Xian-En Zhang,*^c Feng Li*a

^aState Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China. Email: fli@wh.iov.cn ^bUniversity of Chinese Academy of Sciences, Beijing, 100049, China

^cNational Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. Email: zhangxe@ibp.ac.cn

Supplementary Methods.

S1. Protein identification using LC-MS/MS.

The band of interest in SDS-PAGE was excised and was subject to in-gel digestion with 0.025 μ g/ μ L trypsin. The purified VNP samples were digested with 0.025 μ g/ μ L trypsin. The resulting peptides were analyzed on a hybrid quadrupole-TOF LC/MS/MS mass spectrometer (TripleTOF 5600+, AB Sciex) equipped with a nanospray source. Raw data were analyzed with the ProteinPilot Software. Data were searched against the UniProt *E. coli* and *Salmonella* phage P22 database supplemented with the complete amino acid sequences of P22-P₂, EGFP-SP and -30GFP-SP. For estimation of relative abundance of P22-P₂ and SP or SP fusion proteins in the same sample, a spectral sampling method was used.¹

S2. Dynamic light scattering measurement of VNPs.

VNP samples at a concentration of 0.5 mg/mL were filtered by centrifugation at 5, 000 rpm in a 0.22 μ m Ultrafree centrifugal filter unit (Millipore) and then measured on a zetasizer Nano ZS (Malvern) at room temperature (25 °C).

Supplementary Figures

NuBCP-9 CTB-cleavable CTB-cleavable FLAG-tag peptide KLAK peptide P22 CP sequence sequence MDYKDDDDKFSRSLHSLLGSGFLGGSKLAKLAKKLAKKLAKGSGFLGGSHMALNEGQIVTLAV DEIIE<u>TISAITPMAQKAKKYTPPAASMQR</u>SSNTIWMPVEQESPTQEGWDLTDKATGLLELNV AVNMGEPDNDFFQLRADDLRDETAYRRRIQSAARKLANNVELKVANMAAEMGSLVITSPD AIGTNTADAWNFVADAEEIMFSRELNRDMGTSYFFNPQDYKKAGYDLTKRDIFGRIPEEAYR DGTIQRQVAGFDDVLRSPKLPVLTKSTATGITVSGAQSFKPVAWQLDNDGNKVNVDNRFAT VTLSATTGMKRGDKISFAGVKFLGQMAKNVLAQDATFSVVRVVDGTHVEITPKPVALDDVS LSPEQRAYANVNTSLADACAVNILNVKDARTNVFWADDAIRIVSQPIPANHELFAGMKTTSF SIPDVGLNGIFATQGDISTLSGLCRIALWYGVNATRPEAIGVGLPGQTA

Fig. S1. Analysis of the band (a0) having a similar molecular weight of P22 CP in the SP/P22-P₂ lane in Fig. 2A. The band was excised and analyzed using in-gel trypsin digestion and LC-MS/MS, resulting in the peptide coverage map against P22-P₂. The figure shows the complete amino acid sequence of P22-P₂. The underlined amino acid sequences indicate the detected fragments. The result supports that band a0 is probably the products of nonspecific degradation of the P22-P₂ fusion protein, rather than products of protein lysis specifically at the CTB-cleavable sites.

Truncated SP MCRSNAVAEQGR<u>KTQEFTQQSAQYVEAAR</u>KHYDAAEKLNIPDYQEK<u>EDAFMQLVPPAVGA</u> <u>DIMR</u>LFPEKSAALMYHLGANPEKAR<u>QLLAMDGQSALIELTR</u>LSERLTLKPRGK<u>QISSAPHADQ</u> <u>PITGDVSAANKDAIRKQMDAAASKGDVETYR</u>KLKAKLKGIR

Fig. S2. Detection of the truncated SP in the purified SP/P22-P₂ VNPs. The sample was analyzed using trypsin digestion and LC-MS/MS, resulting in the peptide coverage map against the truncated SP. The figure shows the complete amino acid sequence of truncated SP. The underlined sequences indicate detected SP fragments.

NuBCP-9 CTB-cleavable **CTB-cleavable** FLAG-tag KLAK peptide P22 CP peptide sequence sequence MDYKDDDDKFSRSLHSLLGSGFLGGSKLAKLAKKLAKKLAKGSGFLGGSHMALNEGQIVTLAV DEIIE<u>TISAITPMAQKAKKYTPPAASMQR</u>SSNTIWMPVEQESPTQEGWDLTDKATGLLELNV AVNMGEPDNDFFQLR<u>ADDLRDETAYR</u>RRIQSAAR<u>KLANNVELK</u>VANMAAEMGSLVITSPD AIGTNTADAWNFVADAEEIMFSRELNRDMGTSYFFNPQDYKKAGYDLTKRDIFGRIPEEAYR DGTIQRQVAGFDDVLRSPKLPVLTKSTATGITVSGAQSFKPVAWQLDNDGNKVNVDNRFAT VTLSATTGMKRGDKISFAGVKFLGQMAKNVLAQDATFSVVRVVDGTHVEITPKPVALDDVS LSPEQRAYANVNTSLADACAVNILNVKDARTNVFWADDAIRIVSQPIPANHELFAGMKTTSF SIPDVGLNGIFATQGDISTLSGLCRIALWYGVNATRPEAIGVGLPGQTA

Fig. S3. Analysis of band a1 in Fig. 3A. The band was excised and analyzed using in-gel trypsin digestion and LC-MS/MS, resulting in the peptide coverage map against P22-P₂. The figure shows the complete amino acid sequence of P22-P₂. The underlined sequences indicate the detected fragments. The result supports that band a1 is probably the products of nonspecific degradation of the P22-P₂ fusion protein, rather than products of protein lysis specifically at the CTB-cleavable sites.

NuBCP-9 CTB-cleavable **CTB-cleavable** FLAG-tag KLAK peptide P22 CP peptide sequence sequence MDYKDDDDKFSRSLHSLLGSGFLGGSKLAKLAKKLAKLAKGSGFLGGSHMALNEGQIVTLAV DEIIE<u>TISAITPMAQKAKKYTPPAASMQR</u>SSNTIWMPVEQESPTQEGWDLTDKATGLLELNV AVNMGEPDNDFFQLRADDLRDETAYRRIQSAARKLANNVELKVANMAAEMGSLVITSPD AIGTNTADAWNFVADAEEIMFSRELNRDMGTSYFFNPQDYKKAGYDLTKRDIFGRIPEEAYR DGTIQRQVAGFDDVLRSPKLPVLTKSTATGITVSGAQSFKPVAWQLDNDGNKVNVDNRFAT VTLSATTGMKRGDKISFAGVKFLGQMAKNVLAQDATFSVVRVVDGTHVEITPKPVALDDVS LSPEQRAYANVNTSLADACAVNILNVKDARTNVFWADDAIRIVSQPIPANHELFAGMKTTSF **SIPDVGLNGIFATOGDISTLSGLCRIALWYGVNATRPEAIGVGLPGOTA**

EGFP-SP

MVSKGEELFTGVVPILVELDGDVNGHK<u>FSVSGEGEGDATYGK</u>LTLK<u>FICTTGKLPVPWPTLVT</u> <u>TLTYGVQCFSR</u>YPDHMKQHDFFK<u>SAMPEGYVQERTIFFKDDGNYK</u>TRAEVKFEGDTLVNRI ELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQK<u>NGIKVNFK</u>IRHNIEDGSVQLADHYQQ NTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK**GGGGS**GR SNAVAEQGR<u>KTQEFTQQSAQYVEAAR</u>KHYDAAEKLNIPDYQEKEDAFMQLVPPAVGADIM RLFPEKSAALMYHLGANPEKAR<u>QLLAMDGQSALIELTR</u>LSERLTLKPRGK<u>QISSAPHADQPIT</u> <u>GDVSAANKDAIRKQMDAAASKGDVETYR</u>KLKAKLKGIR

Fig. S4. Analysis of band b1 in Fig. 3A. The band was excised and analyzed using in-gel trypsin digestion and LC-MS/MS, resulting in the peptide coverage maps against P22-P₂ (upper) and EGFP-SP (lower). The figure shows the complete amino acid sequences of P22-P₂ (upper) and EGFP-SP (lower). The underlined sequences indicate the detected fragments. The result shows that band b1 also contains partially degraded P22-P₂ in addition to EGFP-SP.

NuBCP-9 CTB-cleavable CTB-cleavable KLAK peptide FLAG-tag peptide sequence sequence P22 CP MDYKDDDDKFSRSLHSLLGSGFLGGSKLAKLAKKLAKLAKGSGFLGGSHMALNEGQIVTLAV DEIIETISAITPMAQK<u>AKKYTPPAASMQR</u>SSNTIWMPVEQESPTQEGWDLTDKATGLLELNV AVNMGEPDNDFFQLRADDLRDETAYRRIQSAARKLANNVELKVANMAAEMGSLVITSPD AIGTNTADAWNFVADAEEIMFSRELNRDMGTSYFFNPQDYKKAGYDLTKRDIFGRIPEEAYR DGTIQRQVAGFDDVLRSPKLPVLTKSTATGITVSGAQSFKPVAWQLDNDGNKVNVDNRFAT VTLSATTGMKRGDKISFAGVKFLGQMAKNVLAQDATFSVVRVVDGTHVEITPKPVALDDVS LSPEQRAYANVNTSLADACAVNILNVKDARTNVFWADDAIRIVSQPIPANHELFAGMKTTSF SIPDVGLNGIFATQGDISTLSGLCRIALWYGVNATRPEAIGVGLPGQTA

Fig. S5. Analysis of band a2 in Fig. 3A. The band was excised and analyzed using in-gel trypsin digestion and LC-MS/MS, resulting in the peptide coverage maps against P22-P₂. The figure shows the complete amino acid sequences of P22-P₂. The underlined sequences indicate the detected fragments. The result supports that band a2 is probably the products of nonspecific degradation of the P22-P₂ fusion protein, rather than products of protein lysis specifically at the CTB-cleavable sites.

NuBCP-9 CTB-cleavable **CTB-cleavable** FLAG-tag peptide sequence seauence **KLAK** peptide P22 CP MDYKDDDDKFSR<u>SLHSLLGSGFLGGSKLAK</u>LAKKLAKLAKGSGFLGGSHMALNEGQIVTLAV DEIIETISAITPMAQKAKKKYTPPAASMQRSSNTIWMPVEQESPTQEGWDLTDKATGLLELNV AVNMGEPDNDFFQLRADDLRDETAYRRRIQSAARKLANNVELKVANMAAEMGSLVITSPD AIGTNTADAWNFVADAEEIMFSR<u>ELNRDMGTSYFFNPODYKKAGYDLTKRDIFGRIPEEAYR</u> DGTIQRQVAGFDDVLRSPKLPVLTKSTATGITVSGAQSFKPVAWQLDNDGNKVNVDNRFAT VTLSATTGMKRGDKISFAGVKFLGQMAKNVLAQDATFSVVRVVDGTHVEITPKPVALDDVS LSPEQRAYANVNTSLADACAVNILNVKDARTNVFWADDAIRIVSQPIPANHELFAGMKTTSF SIPDVGLNGIFATQGDISTLSGLCRIALWYGVNATRPEAIGVGLPGQTA

-30GFP-SP MGASKGEELFDGVVPILVELD<u>GDVNGHEE</u>SVR<u>GEGEGDATEGELTLK</u>FICTTGELPVPWPTL VTTLTYGVQCFSDYPDHMDQHDFFKSAMPEGYVQER<u>TISFKDDGTYKTRAEVKFEGDTLVN</u> <u>RIELK</u>GIDFKEDGNILGHKLEYNFNSHDVYITADKQENGIKAEFEIRHNVEDGSVQLADHYQQ NTPIGDGPVLLPDDHYLSTESALSK<u>DPNEDRDHMVLLEFVTAAGIDHGMDELYK</u>GGGGSGR SNAVAEQGRKTQEFTQQSAQYVEAARKHYDAAEKLNIPDYQEKEDAFMQLVPPAVGADIM <u>RLFPEKSAALMYHLGANPEKARQLLAMDGQSALIELTRLSER</u>LTLKPRGK<u>QISSAPHADQPIT</u> GDVSAANKDAIRKQMDAAASKGDVETYRKLKAKLKGIR

Fig. S6. Analysis of band b2 in Fig. 3A. The band was excised and analyzed using in-gel trypsin digestion and LC-MS/MS, resulting in the peptide coverage maps against P22-P₂ (upper) and -30GFP-SP (lower). The figure shows the complete amino acid sequences of P22-P₂ (upper) and -30GFP-SP (lower). The underlined sequences indicate the detected fragments. The result shows that band b2 also contains partially degraded P22-P₂ in addition to -30GFP-SP.



Fig. S7. TEM images of P22 VNPs with corresponding size distribution obtained from ca. 250 particles. The value on the distribution graph is the average diameter of VNPs shown as mean ± SD. Scale bar: 100 nm.



Fig. S8. DLS measurement of SP/P22 and EGFP-SP/P22-P₂ VNPs before and heat treatment.



Fig. S9. Modification of P22 VNPs with synthetic RGD peptide. (A) SDS-PAGE, showing minor increases of molecular weight of CP and CP-cargo fusion protein. (B) TEM images of RGD-modified P22 VNPs. Scale bars: 200 nm.



Fig. S10. Up-expression of CTB in tumor cells and its subcellular distribution. (A) Western blotting of lysates of different cell lines using an anti-CTB antibody. CTB expression levels varied in different cell lines. Three cell lines, a human breast cancer cell line (MDA-MB-231), a cervical cancer cell line (HeLa) and an African Green Monkey Kidney cell line (Vero) were compared. CTB was detected in MDA-MB-231 cells and HeLa cells but not in Vero cells. (B)

Partial colocalization of CTB (green) with lysosome (red) in MDA-MB-231 cells, revealed by immunofluorescence microscopy using an anti-CTB antibody. Scale bar: 10 µm.

Reference:

1. H. Liu, R. G. Sadygov and J. R. Yates, 3rd, Anal. Chem., 2004, 76, 4193-4201.